Hepatitis B in Solid-Organ Transplant Procedures Other Than Liver.
Transplant is often the best treatment available for patients with end-stage organ failure. Hepatitis B virus infection in transplant procedures other than liver is a major concern because it can be a significant cause of morbidity and mortality after transplant. Due to the increased risk of hepatic complications, such as fibrosing cholestatic hepatitis or histologic deterioration after transplant, systematic use of nucleoside or nucleotide analogues shortly before or at the time of transplant is recommended (tenofovir or entecavir are preferable to lamivudine) in all patients, whatever the baseline histologic evaluation. Sustained viral suppression may result in regression of fibrosis, which in turn may lead to decreased disease-related morbidity and improved survival. Finally, due to the high mortality after nonliver transplant procedures, decompensated cirrhosis from chronic hepatitis B should be considered as a contraindication to nonliver transplant but an indication to combined organ transplant (ie, liver-kidney transplant). Because of the high prevalence of hepatitis B virus exposure in allograft donors and recipients, hepatitis B virus status must be considered during organ allocation. Prevention of hepatitis B virus-related complications in transplant recipients starts with vaccination and donor-recipient matching.
Department of Medicine, Division of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Dina
D
Halegoua-De Marzio
Jonathan M
JM
Fenkel
Cataldo
C
Doria
D000998:Antiviral Agents / Q000627:therapeutic use; D046148:Donor Selection; D006515:Hepatitis B virus / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity*; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000188:drug therapy / Q000401:mortality / Q000635:transmission; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016377:Organ Transplantation / Q000009:adverse effects* / Q000401:mortality; D011183:Postoperative Complications / Q000401:mortality / Q000517:prevention & control / Q000821:virology*; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D000998:Antiviral Agents; D007166:Immunosuppressive Agents